nach oben

Current Oncology Reports

Erschienen in:

01.03.2016 | Gastrointestinal Cancers (J Meyer, Section Editor)

Advances in the Management of Anal Cancer

verfasst von: Diana R. Julie, Karyn A. Goodman

Erschienen in: Current Oncology Reports | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Although anal squamous cell carcinoma (ASCC) is an uncommon malignancy, its incidence has been increasing markedly in recent decades due to its association with human papilloma virus (HPV) infection. The well-established standard of care for localized ASCC consists of the combination of 5-fluorouracil (5FU) and mitomycin (MMC) chemotherapy, concurrent with external beam radiation therapy (EBRT). However, newer techniques are being actively pursued, including the use of newer radiation therapy (RT) technologies, such as intensity-modulated radiation therapy (IMRT). The areas of debate and development include the dosing and timing of MMC delivery, the role of cisplatin chemotherapy as an alternative to MMC, the replacement of the standard 96-h infusion of 5FU with oral capecitabine, the use of targeted chemotherapy agents, and the duration and dose of RT.

Aggarwal A, Duke S, Glynne-Jones R. Anal cancer: are we making progress? Curr Oncol Rep. 2013;15:170–81.CrossRefPubMed

Ajani JA, Winters KA, Gunderson LL, Pederson J, Benson AB, Thomas CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–21.CrossRefPubMed

Eng C, Ahmed S. Optimal management of squamous cell carcinoma of the anal canal: where are we now? Expert Rev Anticancer Ther. 2014;14(8):877–86.CrossRefPubMed

Ghosn M, Jourie HR, Abdayem P, Antoun J, Nasr D. Anal cancer treatment: current status and future perspectives. World J Gastroeneterol. 2015;21(8):2294–302.CrossRef

Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):152–8.CrossRef

Osborne MC, Maykel J, Johnson EK, Steele SR. Anal squamous cell carcinoma: an evolution in disease and management. World J Gastroenterol. 2014;20(36):13052–9.CrossRefPubMedPubMedCentral

Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys. 2009;78(5):1413–9.CrossRef

Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer Supplement. 2008;113(10):2892–900.CrossRef

9.•

Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL. Changing patterns of anal canal carcinoma in the United States. JCO. 2013;31(12):1569–75. This population-based study analyzes over 11,000 cases of ASCC contained within the SEER database, and provides important information regarding ASCC epidemiology. The authors identify key temporal trends in ASCC occurrence and analyze ASCC incidence patterns within the population by stage of disease, gender, age and ethnic background.CrossRef

10.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Ca Cancer J Clin. 2015;65:5–29.CrossRefPubMed

11.

Bazan JG, Luxton G, Kozak MM, Anderson EM, Hancock SL, Kapp DS, et al. Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2013;87(5):983–91.CrossRefPubMed

12.

Tilson P. Anal human papillomavirus and anal cancer. J Clin Pathol. 1997;50:625–34.CrossRef

13.

Bazan JG, Luxton G, Mok EC, Koong AC, Chang DT. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2012;84(3):700–6.CrossRefPubMed

14.

Brooks CJ, Lee YK, Aitken K, Hansen VN, Tait DM, Hawkins MA. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol. 2012;2013(25):155–61.

15.•

Dasgupta T, Rothenstein D, Chou JF, Zhang Z, Wright JL, Saltz LB, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol. 2013;107:189–94. To date, this work represents the largest single-institution study assessing disease outcomes between ASCC patients treated with conventional RT or IMRT. The authors conclude that, rather than leading to recurrences from RT that is too conformal, IMRT yields comparable disease outcomes to conventional RT.CrossRefPubMed

16.

Devisetty K, Mell LK, Salama JK, Schomas DA, Miller RC, Jani AB, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. Radiother Oncol. 2009;93:298–301.CrossRefPubMed

17.•

Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2012;86(1):27–33. This Phase II trial evaluated acute toxicities among ASCC patients undergoing treatment with DP-IMRT, and compared these to acute toxicity rates observed among those treated with conventional RT in the RTOG9811 trial. While there was no substantial difference in the rate of grade 2+ GI or GU toxicity observed, the authors did report significant improvement in the rates of grade 2+ HT, grade 3+ GI toxicity and grade 3+ dermatologic toxicity with the use of DP-IMRT. This study adds to a growing body of literature demonstrating that the use of IMRT in ASCC treatment can significantly affect the acute treatment-related toxicities observed.

18.

Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(5):1431–7.CrossRefPubMed

19.

Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–61.CrossRefPubMed

20.

Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw. 2010;8(1):123–9.PubMed

21.

Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol. 2008;87:383–90.CrossRefPubMed

22.

Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25(9):4581–6.CrossRefPubMed

23.

Simpson JAD, Scholefield JH. Diagnosis and management of anal intraepithelial neoplasia and anal cancer. BMJ. 2011;343:d6818.CrossRefPubMed

24.

Berry JM, Jay N, Cranston RD, Darragh TM, Holly EA, Welton ML, Palefsy JM (2014) Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men.

25.

Fleshner PR, Chalasani S, Chang GJ, Levien DH, Hyman NH, Buie WD. Practice parameters for anal squamous neoplasms. Dis Colon Rectum. 2008;51(1):2–9.CrossRefPubMed

26.

Kreuter A, Potthoff A, Brockmeyer NH, Gambichlet T, Swoboda J, Stucker M, et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol. 2014;162:1269–77.CrossRef

27.

Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg. 2005;92:1133–6.CrossRefPubMed

28.

Watson AJ, Smith BB, Whitehead MR, Skyes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg. 2006;76:715–7.CrossRefPubMed

29.

Rabkin CS, Biggar RJ, Melbye M, Curtis RE. Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors. Am J Epidemiol. 1992;136(1):54–8.PubMed

30.

Frisch M. On the etiology of anal squamous carcinoma. Br Med Bull. 2002;49:194–209.

31.

Fraunholz I, Rabeneck D, Weiss C, Rodel C. Combined-modality treatment for anal cancer: current strategies and future directions. Strahlenther Onkol. 2010;186(7):361–6.CrossRefPubMed

32.

Nigro ND, Vaitkevicius VK, Considine Jr B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974;17(3):354–6.CrossRefPubMed

33.

Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51(10):1826–9.CrossRefPubMed

34.

Cummings BJ, Keane TJ, O’Sullivan B, Wong CS, Catton CN. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–25.CrossRefPubMed

35.

Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Dis Colon Rectum. 1992;35(5):422–9.CrossRefPubMed

36.

Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin, UK Co-ordinating Committee on Cancer Research. UKCCCR Anal Cancer Trial Working Party. Lancet. 1996;348(9034):1049–54.CrossRef

37.

Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040–9.PubMed

38.

Deutsch E, Lemanski C, Pignon JP, Levy A, Delarocheforiere A, Martel-Lafay I, et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. 2013;24:2834–8.CrossRefPubMed

39.

Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.PubMed

40.

Olivatto LO, Cabral V, Rosa A, Bezerra M, Santarem E, Fassizoli A, et al. Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. Int J Radiat Oncol Biol Phys. 2011;79(2):490–5.CrossRefPubMed

41.

Gunderson LL, Winter KA, Ajani JA, Pederson JE, Moughan J, Benson 3rd AB, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–51.CrossRefPubMedPubMedCentral

42.••

James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14(6):516–24. The ACT II trial, containing over 9000 patients, is the largest RCT of ASCC undertaken to date. This trial compared treatment with CRT using MMC and 5FU or cisplatin and 5FU, and reported similar disease outcomes and clinically significant toxicities. It is in large part based upon this trial that CRT with 5FU and MMC has remained the standard of care for ASCC patients.

43.

Nilsson PJ, Svensson C, Goldman S, Ljungqvist O, Glimelius B. Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys. 2005;61(1):92–102.CrossRefPubMed

44.

Meropol NJ, Niedzwiecki D, Shank B, Day JM, Hopkins J, Tepper J, et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol. 2008;26(19):3229–334.CrossRefPubMed

45.••

Peiffert D, Tournier-Rangeard L, Gerard JP, Lemanski C, Francois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941–8. This Phase III trial evaluated the roles of both cisplatin-based induction chemotherapy and RT dose escalation in the treatment of ASCC. Using CFS as the primary endpoint, the authors concluded that neither induction chemotherapy nor increased RT dose conferred a significant advantage. Though these two treatment modalities continue to be explored, based upon the results of this RCT, neither is currently included in gold standard ASCC treatment.

46.•

Yeung R, McConnell Y, Roxin G, Banerjee R, Roldan Urgoiti GB, MacLean AR, et al. One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity. Curr Oncol. 2014;21(3):e449-–456. As discussed, there is ongoing debate regarding the ideal dosage and timing of MMC administration in ASCC treatment to maximize outcomes and reduce toxicity. This large retrospective study is the first to directly compare ASCC patients treated with one or two concurrent cycles of MMC. The authors report comparable disease outcomes in the two groups, with significantly reduced hematologic and dermatologic toxicity in the single cycle group. This study lends support to the notion that the second MMC cycle can be safely omitted.CrossRefPubMedPubMedCentral

47.

Thind G, Johal B, Follwell M, Kennecke HF. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. Radiat Oncol. 2014;9:124.CrossRefPubMedPubMedCentral

48.•

Goodman KA, Rothenstein D, Cambridge L, Wu A, Cercek A, Saltz LB. Capecitabine plus mitomycin in patients undergoing definitive chemoradiation for anal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2014;90(1):S32–33. This retrospective review of ASCC patients is one of the first to systematically compare CRT with 5FU or oral Capecitabine. The authors concluded that oral capecitabine reduced clinically significant HT. This study suggests the possibility of a prospective study to compare 5FU and capecitabine with regard to outcomes and toxicities.

49.

Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, et al. EXTRA—a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008;72(1):119–26.CrossRefPubMed

50.

Olivatto LO, Vieira FM, Pereira BV, Victorino AP, Bezerra M, Araujo CM, et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013;119(16):2973–80.CrossRefPubMed

51.

Paliga A, Onerheim R, Golofan A, Chong G, Spatz A, Niazi T, et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer. 2012;107:1864–8.CrossRefPubMedPubMedCentral

52.

Garg M, Lee JY, Kachnic L, Catalano PJ, Henry DH, Cooley TP et al. (2012) Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. 30: Suppl; Abstr 4030.

53.

Phase II study of concomitant intensity-modulated radiotherapy combined to capecitabine, mitomycin and panitumumab in patients with stage II-IIIB squamous-cell carcinoma of the anal canal. Available from: http://clinicaltrials.gov/show/NCT01843452.

54.

Vectibix for the treatment of anal cancer (VITAL). Available from: http://clinicaltrials.gov/show/NCT01285778.

55.

Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of radiation therapy oncology group trials 87-04 and 98-11. JCO. 2010;28(34):5061–6.CrossRef

56.

Allal AS, Mermillod B, Roth AD, Marti MC, Kurtz JM. The impact of treatment factors on local control in T2-T3 anal carcinomas treated by radiotherapy with or without chemotherapy. Cancer. 1997;79(12):2329–35.CrossRefPubMed

57.

Weber DC, Kurtz JM, Allal AS. The impact of gap duration on local control in anal canal carcinoma treated with split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys. 2001;50(3):657–80.CrossRef

58.

Graf R, Wust P, Hildebrandt B, Gogler H, Ullrich R, Herrmann R, et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology. 2003;65(1):14–22.CrossRefPubMed

59.

Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys. 2003;56(5):1259–73.CrossRefPubMed

60.

Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys. 1997;39(3):651–7.CrossRefPubMed

61.

Meyer A, Meier Zu Eissen J, Karstens JH, Bremer M. Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome. Acta Oncologica. 2006;45(6):728–35.CrossRefPubMed

62.

Myerson RJ, Outlaw ED, Chang A, Birnbaum EH, Fleshman JW, Grigsby PW, et al. Radiotherapy for epidermoid carcinoma of the anus: thirty years’ experience. Int J Radiat Oncol Biol Phys. 2009;75(2):428–35.CrossRefPubMed

63.

Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, et al. Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol. 2008;87(3):367–75.CrossRefPubMed

64.

Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys. 1989;17(6):1153–60.CrossRefPubMed

65.

Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol. 2007;13(6):895–900.CrossRefPubMedPubMedCentral

66.

Konski A, Garcia Jr M, John M, Krieg R, Pinover W, Myerson R, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys. 2008;72(1):114–8.CrossRefPubMedPubMedCentral

67.

Chuong MD, Freilich JM, Hoffe SE, Fulp W, Weber JM, Almhanna K, et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6(2):39–45.PubMedPubMedCentral

68.

Julie DA, Oh JH, Apte AP, Deasy JO, Tom A, Wu AJ, et al. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. Acta Oncol May. 2015;18:1–9.

69.

Mitchell MP, Abboud M, Eng C, Beddar AS, Krishnan S, Delclos ME, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014;37(5):461–6.CrossRefPubMed

70.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Anal carcinoma version 1.2016. Available at: http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf.

71.

Glynne-Jones R, James R, Meadows H, Begum R, Cunningham D, Northover J, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. J Clin Oncol. 2012;30(suppl):abstr 4004.

72.

Papaconstantinou HT, Bullard KM, Rothenberger DA, Madoff RD. Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Colorectal Dis. 2006;8(2):124–9.CrossRefPubMed

73.

van der Wal BC, Cleffken BI, Gulec B, Kaufman HS, Choti MA. Results of salvage abdominoperineal resection for recurrent anal carcinoma following combined chemoradiation therapy. J Gastrointest Surg. 2001;5(4):383–7.CrossRefPubMed

74.

Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum. 2005;48(1):16–22.CrossRefPubMed

75.

Hallemeier CL, You YN, Larson DW, Dozois EJ, Nelson H, Klein KA, et al. Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Dis Colon Rectum. 2014;57(4):442–8.CrossRefPubMed

76.

Flam MS, John MJ, Mowry PA, Lovalvo LJ, Ramalho LD, Wade J. Definitive combined modality therapy of carcinoma of the anus. A report of 30 cases including results of salvage therapy in patients with residual disease. Dis Colon Rectum. 1987;30(7):495–50.CrossRefPubMed

77.

Golub DV, Civelek AC, Sharma VR. A regimen of taxol, ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract. 2011;2011:163736.PubMedPubMedCentral

78.

Kim S, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol. 2013;24:3045–50.CrossRefPubMed

79.

Barmettler H, Komminoth P, Schmid M, Duerr D. Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer. Case Rep Oncol. 2012;5(2):428–33.CrossRefPubMedPubMedCentral

Titel: Advances in the Management of Anal Cancer
verfasst von: Diana R. Julie
Karyn A. Goodman
Publikationsdatum: 01.03.2016
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 3/2016
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-016-0503-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Advances in the Management of Anal Cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer

Particle Radiation Therapy for Gastrointestinal Cancers

Can We Be Less Radical with Surgery for Early Cervical Cancer?

Radiation Toxicity to the Cardiovascular System

Health Services Research and Regionalization of Care—From Policy to Practice: the Ontario Experience in Head and Neck Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie